Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Mondaycom Ltd (MNDY) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Mondaycom LtdTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Mondaycom Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.58 (market cap $9.43B), while Mondaycom Ltd trades at $84.58 (market cap $3.70B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.5× Mondaycom Ltd's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.

BIOMNDY
Market Cap
$9.43B$3.70B
Sector
HealthTechnology
52-Week High
$356.25$219.15
52-Week Low
$241.71$58.81
Enterprise Value
$9.18B$2.86B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.

The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.

Mondaycom Ltd

MNDY trades at $84.52, down 4.63% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS of $1.48 beating estimates by 33%, revenue growth of 22% year-over-year, and robust gross margins of 88.74%. However, technical indicators are neutral with support at $83 and resistance at $89. Recent news highlights AI product growth but weaker Q3 revenue guidance caused a sell-off.

Outlook remains cautiously optimistic with a $113.38 consensus price target implying 34% upside. Key risks include slowing revenue growth guidance and competitive pressures. The 76% buy rating from analysts supports long-term potential, but near-term volatility may persist due to execution concerns and market sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Mondaycom Ltd

Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.

Read more on MNDY